Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emactuzumab - SynOx Therapeutics

Next Previous
Search
Drug Profile

Emactuzumab - SynOx Therapeutics

Alternative Names: RG-7155; RO-5509554

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Roche; SynOx Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumour of tendon sheath
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • Discontinued Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 14 Apr 2025 Emactuzumab receives Fast track status from the US FDA for Giant cell tumour of tendon sheath in USA
  • 03 Jul 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Spain, Spain, Belgium (IV) prior to July 2024 (SynOx Therapeutics pipeline) (July 2024, Roche pipeline, July 2024)
  • 03 Jul 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA, France (IV) prior to July 2024 (SynOx Therapeutics pipeline) (July 2024, Roche pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top